CW November 2000
Volume 9Issue Number 11 November 2000 ISSN 10593802 Modified Interleukin 2 Reduces its ToxicityThe natural cytokine interleukin 2 is used in cancer patients to stimulate immune cells. This anti-cancer treatment produces severe toxicity probably by natural killer (NK) cells. A variant form of interleukin 2 can specifically interact with activated T cells over natural killer cell and produce lesser severe side effects.
Go to Previous Page Go to Next Page Source & Additional Reading A. B. Shanafelt, Nature Biotechnology, November 2000. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW November 2000Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
